CLDX Celldex Therapeutics Inc

Simplify Asset Management Inc. recently invested $2.20 million in Celldex Therapeutics, acquiring 85,000 shares, representing 0.13% of the company. Celldex, a clinical-stage biopharmaceutical company, disappointed with a Q3 EPS miss and has negative margins, yet analysts assign a "Moderate Buy" rating with an average $44.10 price target. This comes despite an insider selling a significant portion of shares in November.

Barclays has increased its price target for Celldex Therapeutics (CLDX) to $24 from $21, while reaffirming an Equal Weight rating. This adjustment is part of its 2026 outlook for the biotechnology sector. Concurrently, Celldex Therapeutics initiated a global Phase 3 trial for barzolvolimab, a specialized monoclonal antibody, to evaluate its efficacy and safety in treating cold urticaria and symptomatic dermographism.

Corient Private Wealth LLC recently acquired 201,717 shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the second quarter, valued at approximately $4.11 million. This makes Corient a significant new institutional holder of the biopharmaceutical company's stock, though other institutions like American Century Companies Inc. hold even larger stakes. Insider Richard M. Wright recently sold a substantial portion of his shares, while analysts have a "Moderate Buy" consensus rating with a $44.10 price target despite the company missing its last quarterly EPS estimate.

Barclays has increased its price target for Celldex Therapeutics (CLDX) to $24 from $21, reaffirming an "Equal Weight" rating, considering its 2026 outlook for the biotechnology sector. The adjustment comes as Celldex initiated a global Phase 3 trial for barzolvolimab, a crucial drug for cold urticaria and symptomatic dermographism, which has shown promising results in earlier studies. Despite the potential, the article suggests that certain AI stocks might offer greater upside and less risk than CLDX.

Celldex Therapeutics (CLDX) has seen a recent uptick in its share price, prompting investors to assess its valuation. Despite the recent gains, potentially indicating improving momentum, the clinical-stage biotech faces a volatile history with a negative 3-year total shareholder return. The company's price-to-book ratio of 2.8x suggests it's modestly valued compared to some peers but slightly expensive relative to the broader US biotech industry, reflecting ongoing risks such as trial setbacks and potential dilution.

Barclays has increased its price target for Celldex Therapeutics (NASDAQ:CLDX) to $24.00, though it maintains an "underweight" rating, suggesting a potential 9.62% downside. This rating adjustment follows Celldex missing its Q3 earnings estimates and insider stock sales, even as the consensus analyst rating remains a "Moderate Buy" with an average target of $44.10. Other analysts have provided conflicting ratings, ranging from "Strong Buy" to "Sell," reflecting general mixed sentiment towards the biopharmaceutical company.